{
    "medicine_id": "dad7a9d6a5d7d7304547a2f474352a40939f88bc",
    "platform_id": "DB00103",
    "metadata": {
        "name": "Fabrazyme 35 mg Injection powder for solution",
        "composition": "35 mg Agalsidase beta",
        "clinical_particulars": {
            "therapeutic_indications": "Agalsidase beta is indicated in the treatment of Fabry disease L16383",
            "contraindications": {
                "disease": "Data regarding overdoses of agalsidase beta are not readily available L16383 Patients experiencing an overdose of agalsidase beta may experience an increased incidence and severity of adverse effects L16383 Overdose can be managed through the use of symptomatic and supportive measures",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "Agalsidase beta is a recombinant human \u03b1 galactosidase A used as enzyme replacement therapy in the treatment of Fabry disease L16398 It has a long duration of action and a wide therapeutic index L16383 Patients should be counselled regarding the risk of infusion related reactions and hypersensitivity L16383",
                "excipients": "NA",
                "incompatibilities": [
                    {
                        "drugbank-id": "DB00608",
                        "description": "The therapeutic efficacy of Agalsidase beta can be decreased when used in combination with Chloroquine"
                    },
                    {
                        "drugbank-id": "DB00798",
                        "description": "The therapeutic efficacy of Agalsidase beta can be decreased when used in combination with Gentamicin"
                    },
                    {
                        "drugbank-id": "DB01118",
                        "description": "The therapeutic efficacy of Agalsidase beta can be decreased when used in combination with Amiodarone"
                    }
                ]
            }
        },
        "revision_date": "2023-05-14"
    }
}